This report provides a comprehensive analysis of the global Lanreotide Injection market, which is projected to experience steady growth through 2032. Primarily used to manage acromegaly and neuroendocrine tumor symptoms, the market is segmented by formulation type and application across major regions including the Americas, APAC, and Europe. The study examines key industry players, competitive strategies, and emerging trends, offering detailed insights into market drivers, revenue projections, and significant opportunities within the long-acting somatostatin analogue sector.

Market Overview

The global Lanreotide Injection market size is predicted to grow from US$ 511 million in 2025 to US$ 681 million in 2032, representing an expected compound annual growth rate (CAGR) of 4.3% from 2026 to 2032.

Product Profile

Lanreotide, sold under the brand name Somatuline among others, is a long-acting analogue of somatostatin (similar to octreotide). It is utilized in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome.

Clinical Indications and Usage

• United States and Canada: Lanreotide is indicated specifically for the treatment of acromegaly.
• United Kingdom: In addition to acromegaly, it is indicated for the treatment of thyrotrophic adenoma, a rare tumor of the pituitary gland that secretes TSH.
• General Research: Lanreotide demonstrates activity against non-endocrine tumors and, alongside other somatostatin analogues, is currently being studied as a potential general antitumor agent.

Regional Market Analysis

• United States: The market for Lanreotide Injection is projected to experience growth from 2025 through 2032.
• China: The market for Lanreotide Injection is projected to experience growth from 2025 through 2032.
• Europe: The market for Lanreotide Injection is projected to experience growth from 2025 through 2032.

Market Segmentation

By Type

• Sustained Release Formulation
• Long-acting Formula

By Application

• Hospital
• Clinic
• Others

By Geography

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

Key Players

The following companies have been profiled based on primary expert input and analysis of company coverage, product portfolios, and market penetration:

• Ipsen
• Cipla

Market Concentration

In 2025, the two largest global companies in the Lanreotide Injection sector are expected to hold a significant portion of the total market revenue share.

About the Report

Produced by LP Information, Inc. (LPI), the “Lanreotide Injection Industry Forecast” provides a comprehensive analysis of the global landscape. The report reviews total world Lanreotide Injection sales in 2025 and provides detailed projections for 2026 through 2032, broken down by region, market sector, and sub-sector in US$ millions.

Scope and Methodology

This Insight Report highlights key trends regarding:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments and M&A activity

Furthermore, the report analyzes the strategies of leading global companies, focusing on their Lanreotide Injection portfolios, capabilities, market entry strategies, market positions, and geographic footprints. The study utilizes a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs to evaluate market drivers, trends, and affecting factors, identifying emerging pockets of opportunity.

Key Questions Addressed

• What is the 10-year outlook for the global Lanreotide Injection market?
• What factors are driving Lanreotide Injection market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Lanreotide Injection market opportunities vary by end market size?
• How does Lanreotide Injection break out by Type and by Application?

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Lanreotide Injection Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Lanreotide Injection by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Lanreotide Injection by Country/Region, 2021, 2025 & 2032

  • 2.2 Lanreotide Injection Segment by Type

    • 2.2.1 Sustained Release Formulation

    • 2.2.2 Long-acting Formula

    • 2.2.3 Lanreotide Injection Sales by Type

      • 2.2.3.1 Global Lanreotide Injection Sales Market Share by Type (2021-2026)
      • 2.2.3.2 Global Lanreotide Injection Revenue and Market Share by Type (2021-2026)
      • 2.2.3.3 Global Lanreotide Injection Sale Price by Type (2021-2026)

  • 2.3 Lanreotide Injection Segment by Application

    • 2.3.1 Hospital

    • 2.3.2 Clinic

    • 2.3.3 Others

    • 2.3.4 Lanreotide Injection Sales by Application

      • 2.3.4.1 Global Lanreotide Injection Sale Market Share by Application (2021-2026)
      • 2.3.4.2 Global Lanreotide Injection Revenue and Market Share by Application (2021-2026)
      • 2.3.4.3 Global Lanreotide Injection Sale Price by Application (2021-2026)

• 3 Global by Company

  • 3.1 Global Lanreotide Injection Breakdown Data by Company

    • 3.1.1 Global Lanreotide Injection Annual Sales by Company (2021-2026)

    • 3.1.2 Global Lanreotide Injection Sales Market Share by Company (2021-2026)

  • 3.2 Global Lanreotide Injection Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Lanreotide Injection Revenue by Company (2021-2026)

    • 3.2.2 Global Lanreotide Injection Revenue Market Share by Company (2021-2026)

  • 3.3 Global Lanreotide Injection Sale Price by Company

  • 3.4 Key Manufacturers Lanreotide Injection Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Lanreotide Injection Product Location Distribution

    • 3.4.2 Players Lanreotide Injection Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Lanreotide Injection by Geographic Region

  • 4.1 World Historic Lanreotide Injection Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Lanreotide Injection Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Lanreotide Injection Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Lanreotide Injection Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Lanreotide Injection Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Lanreotide Injection Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Lanreotide Injection Sales Growth

  • 4.4 APAC Lanreotide Injection Sales Growth

  • 4.5 Europe Lanreotide Injection Sales Growth

  • 4.6 Middle East & Africa Lanreotide Injection Sales Growth

• 5 Americas

  • 5.1 Americas Lanreotide Injection Sales by Country

    • 5.1.1 Americas Lanreotide Injection Sales by Country (2021-2026)

    • 5.1.2 Americas Lanreotide Injection Revenue by Country (2021-2026)

  • 5.2 Americas Lanreotide Injection Sales by Type (2021-2026)

  • 5.3 Americas Lanreotide Injection Sales by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Lanreotide Injection Sales by Region

    • 6.1.1 APAC Lanreotide Injection Sales by Region (2021-2026)

    • 6.1.2 APAC Lanreotide Injection Revenue by Region (2021-2026)

  • 6.2 APAC Lanreotide Injection Sales by Type (2021-2026)

  • 6.3 APAC Lanreotide Injection Sales by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Lanreotide Injection by Country

    • 7.1.1 Europe Lanreotide Injection Sales by Country (2021-2026)

    • 7.1.2 Europe Lanreotide Injection Revenue by Country (2021-2026)

  • 7.2 Europe Lanreotide Injection Sales by Type (2021-2026)

  • 7.3 Europe Lanreotide Injection Sales by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Lanreotide Injection by Country

    • 8.1.1 Middle East & Africa Lanreotide Injection Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Lanreotide Injection Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Lanreotide Injection Sales by Type (2021-2026)

  • 8.3 Middle East & Africa Lanreotide Injection Sales by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Lanreotide Injection

  • 10.3 Manufacturing Process Analysis of Lanreotide Injection

  • 10.4 Industry Chain Structure of Lanreotide Injection

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Lanreotide Injection Distributors

  • 11.3 Lanreotide Injection Customer

• 12 World Forecast Review for Lanreotide Injection by Geographic Region

  • 12.1 Global Lanreotide Injection Market Size Forecast by Region

    • 12.1.1 Global Lanreotide Injection Forecast by Region (2027-2032)

    • 12.1.2 Global Lanreotide Injection Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Lanreotide Injection Forecast by Type (2027-2032)

  • 12.7 Global Lanreotide Injection Forecast by Application (2027-2032)

• 13 Key Players Analysis

  • 13.1 Ipsen

    • 13.1.1 Ipsen Company Information

    • 13.1.2 Ipsen Lanreotide Injection Product Portfolios and Specifications

    • 13.1.3 Ipsen Lanreotide Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 Ipsen Main Business Overview

    • 13.1.5 Ipsen Latest Developments

  • 13.2 Cipla

    • 13.2.1 Cipla Company Information

    • 13.2.2 Cipla Lanreotide Injection Product Portfolios and Specifications

    • 13.2.3 Cipla Lanreotide Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 Cipla Main Business Overview

    • 13.2.5 Cipla Latest Developments

• 14 Research Findings and Conclusion